Claims for Patent: 6,465,464

Summary for Patent: 6,465,464

Title:	Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
Abstract:	The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death ##STR1## wherein the 2-imidazolin-2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy, or pharmaceutically acceptable salts thereof and mixtures thereof. Such noxious action may result from ischemia, e.g. spinal ischemia.
Inventor(s):	Wheeler; Larry A. (Irvine, CA), Woldemussie; Elizabeth (Laguna Niguel, CA), Lai; Ronald K. (Irvine, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/080,451
Patent Claims:	1. A method of providing neural protection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death ##STR7## or pharmaceutically acceptable salts thereof and mixtures thereof. 2. The method of claim 1 wherein the noxious action is a result of a crushed or compressed nerve. 3. The method of claim 1 wherein the noxious action is a result of ischemia. 4. The method of claim 1 wherein the noxious action is a result of spinal ischemia. 5. The method of claim 1 wherein the noxious action is glaucomatous optic neuropathy. 6. The method of claim 1 wherein the noxious action is atrophy associated with dry ARMD. 7. The method of claim 1 wherein said noxious action is a laser light directed into the eye in a procedure for treatment of wet ARMD. 8. The method of claim 1 wherein the noxious action is ischemia secondary to glaucoma. 9. The method of claim 1 wherein the noxious action is photoreceptor cell damage associated with retinitis pigmentosa. 10. The method of claim 4 wherein said compound is administered intrathecally, epidurally or systemically. 11. The method of claim 5 wherein said compound is administered orally or by injection. 12. The method of claim 1 wherein said noxious action is a result of glutamate induced excitotoxic effects on nerve cells. 13. The method of claim 1 wherein said compound is administered in combination with an NMDA antagonist. 14. The method of claim 8 wherein said NMDA antagonist is memantine. 15. The method of claim 1 wherein said compound is administered in an amount sufficient to achieve a serum concentration of from 0.01 nM to 500 nM. 16. The method of claim 1 wherein said compound is administered topically.